CX-2051

Varseta-M
DEVELOPMENT STEP phase-1
SPONSOR MATRIX CytomX Therapeutics [CTMX]
MECHANISM TARGET // UNMAPPED_TARGET

[THERAPEUTIC_PROFILE]

Target Indications

mCRC

Mechanism Abstract

CX-2051 is a conditionally activated ADC directed toward the epithelial cell adhesion molecule (EpCAM), with potential applicability across multiple EpCAM-expressing epithelial cancers. EpCAM is a validated anti-cancer target for which systemic therapies not yet been developed due to widespread expression on normal tissues. CX-2051 is designed to open a therapeutic window for a systemically administered anti-EpCAM ADC.

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED1
RECRUITING STATUS1
COMPLETED RUNS0
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
➔
P-1NCT06265688
Solid Tumor, Adult
N=160Est. Finish: 2029-03-31
First In Human Study of CX-2051 in Advanced Solid Tumors
recruiting